Intelligent Medical Technologies

IMT-Bio (Intelligent Medical Technologies) is a South Korean biotechnology company dedicated to developing next-generation immunotherapies for cancer and autoimmune diseases. The company's research focus spans three primary pillars: CAR-T cell therapies for solid tumors, exosome-based drug delivery systems, and bispecific antibodies. Its proprietary IMT-Exo platform leverages engineered exosomes to deliver therapeutic payloads with high specificity and reduced toxicity. Currently in the pre-clinical stage, IMT-Bio aims to address significant unmet needs in oncology by overcoming the challenges of the immunosuppressive tumor microenvironment.